1. Home
  2. IPHA vs SPKL Comparison

IPHA vs SPKL Comparison

Compare IPHA & SPKL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • IPHA
  • SPKL
  • Stock Information
  • Founded
  • IPHA 1999
  • SPKL 2021
  • Country
  • IPHA France
  • SPKL United States
  • Employees
  • IPHA N/A
  • SPKL N/A
  • Industry
  • IPHA Biotechnology: Pharmaceutical Preparations
  • SPKL
  • Sector
  • IPHA Health Care
  • SPKL
  • Exchange
  • IPHA Nasdaq
  • SPKL Nasdaq
  • Market Cap
  • IPHA 148.3M
  • SPKL 174.6M
  • IPO Year
  • IPHA 2019
  • SPKL 2023
  • Fundamental
  • Price
  • IPHA $1.79
  • SPKL $10.66
  • Analyst Decision
  • IPHA Strong Buy
  • SPKL
  • Analyst Count
  • IPHA 1
  • SPKL 0
  • Target Price
  • IPHA $11.50
  • SPKL N/A
  • AVG Volume (30 Days)
  • IPHA 779.8K
  • SPKL 44.7K
  • Earning Date
  • IPHA 09-12-2024
  • SPKL 01-01-0001
  • Dividend Yield
  • IPHA N/A
  • SPKL N/A
  • EPS Growth
  • IPHA N/A
  • SPKL N/A
  • EPS
  • IPHA N/A
  • SPKL 0.19
  • Revenue
  • IPHA $36,202,722.00
  • SPKL N/A
  • Revenue This Year
  • IPHA N/A
  • SPKL N/A
  • Revenue Next Year
  • IPHA $101.65
  • SPKL N/A
  • P/E Ratio
  • IPHA N/A
  • SPKL $57.45
  • Revenue Growth
  • IPHA N/A
  • SPKL N/A
  • 52 Week Low
  • IPHA $1.29
  • SPKL $10.18
  • 52 Week High
  • IPHA $3.51
  • SPKL $11.95
  • Technical
  • Relative Strength Index (RSI)
  • IPHA 45.92
  • SPKL 61.06
  • Support Level
  • IPHA $1.64
  • SPKL $10.63
  • Resistance Level
  • IPHA $1.87
  • SPKL $10.66
  • Average True Range (ATR)
  • IPHA 0.12
  • SPKL 0.02
  • MACD
  • IPHA -0.04
  • SPKL 0.00
  • Stochastic Oscillator
  • IPHA 28.66
  • SPKL 75.00

About IPHA Innate Pharma S.A. ADS

Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.

About SPKL Spark I Acquisition Corp.

Spark I Acquisition Corp is a Blank check company.

Share on Social Networks: